View More Recent Stories
-
H.C. Wainwright Reiterates Buy Rating on WAVE Life Sciences (WVE)
-
Truist: 'WAVE Life Sciences (WVE) Remains One of Our Favorite Stocks for 2025'
-
WAVE Life Sciences (WVE) PT Raised to $21 at JPMorgan
-
WAVE Life Sciences (WVE) Tops Q4 EPS by 34c
-
Jefferies Starts WAVE Life Sciences (WVE) at Buy
-
WAVE Life Sciences (WVE) announces phase 1 of clinic trial of WVE-007
-
WAVE Life Sciences (WVE) spreader of December 15 and 17.50 calls
-
JPMorgan is out with its 2025 outlook for biotech stocks
-
WAVE Life Sciences (WVE) PT Raised to $36 at Truist Securities
-
Leerink Partners Reiterates Outperform Rating on WAVE Life Sciences (WVE)
-
WAVE Life Sciences (WVE) PT Raised to $15 at RBC Capital
-
H.C. Wainwright Reiterates Buy Rating on WAVE Life Sciences (WVE)
-
Jones Trading Reiterates Buy Rating on WAVE Life Sciences (WVE)
-
WAVE Life Sciences (WVE) Announces First-Ever Therapeutic RNA Editing in Humans Achieved in RestorAATion-2 Trial of WVE-006 in Alpha-1 Antitrypsin Deficiency
-
WAVE Life Sciences (WVE) PT Raised to $19 at B.Riley
-
JPMorgan Reinstates WAVE Life Sciences (WVE) at Overweight
-
WAVE Life Sciences (WVE) Prices Upsized $200M Share and Warrant Offering
-
Mizuho Reiterates Outperform Rating on WAVE Life Sciences (WVE)
-
B.Riley Reiterates Buy Rating on WAVE Life Sciences (WVE)
-
WAVE Life Sciences (WVE) no longer intends to offers ordinary shares
-
After-hours movers: KB Home, Progress Software, Worthington Industries and more
-
WAVE Life Sciences (WVE) Announces Proposed Public Offering of Ordinary Shares and Pre-Funded Warrants
-
WAVE Life Sciences (WVE) PT Raised to $22 at H.C. Wainwright
-
Jones Trading Reiterates Buy Rating on WAVE Life Sciences (WVE)
-
WAVE Life Sciences (WVE) Announces Positive Interim Data from FORWARD-53 Trial of WVE-N531
-
UBS Starts LEM Holding SA (LEHN:SW) at Buy
-
Jones Trading Reiterates Buy Rating on WAVE Life Sciences (WVE)
-
WAVE Life Sciences (WVE) Receives FDA Rare Pediatric Disease Designation for WVE-N531 for the Treatment of Duchenne Muscular Dystrophy
-
Jones Trading Starts WAVE Life Sciences (WVE) at Buy
-
WAVE Life Sciences (WVE) Misses Q2 EPS by 4c
-
Truist Securities Defending WAVE Life Sciences (WVE): 'We're Buyers Of Weakness Today'
-
WAVE Life Sciences (WVE) Announces Positive Results from Phase 1b/2a SELECT-HD Trial

